Wingard, M.D. is the Price Eminent Scholar and Professor of Medicine, Deputy Director for Research of the UF Health Cancer Cente r, and Director of the Bone Marrow Transplant Program for the University of Florida. Dr. Wingard is a renowned expert in bone and stem cell transplantation as well as active clinical researcher. He also oversees the pediatric and adult stem cell transplan tation programs and in such capacity coordinates the care of patients receiving high -dose chemotherapy and stem cell transplantation at the University of Florida including children with CNS tumors. Dr. Wingard has extensive experience in the collection and dissemination of autologous and allogeneic cellular products to patients at multiple FACT -accredited institutions and will assist Dr. Mitchell in the multi- site coordination of collection of leukapheresis specimens, peripheral blood stem cell products, bar -coded storage and dissemination of cellular products, and batch records for the cellular products generated on this protocol. The UF stem and bone marrow transplant program maintains state-of-the-art facilities and technologies for autologous cell product delivery to pediatric and adult patients. http://hemonc.medicine.ufl.edu/about -us/meet -the-team/john -r-wingard -md/ David R. Nelson, M.D. is Professor of Medicine, Molecular Genetics and Microbiology, Director, UF Clinical and Translational Science Institute, and Associate Dean for Clinical Research. He has met with Dr. Mitchell several times to outline the many facets of this protocol that can leverage the extens ive clinical research infrastructure supported by the NIH -funded CTSI at the University of Florida. Dr. Nelson will oversee the coordination of the multi -site collection and registration of clinical data into a clinical database, coordinate the availability of the clinical research hospital and infusion center for this protocol, as well as coordinate the interaction between clinical research sites. Additionally, the CTSI maintains extensive biorepository and tissue distribution capabilities as one of only 12 CAP -certified biorepositories in the United States. The CTSI -supported biorepository and distribution capabilities will be leveraged to coordinate the collection of tumor tissues and Re-MATC H Protocol Page 33 of 106 Version: 20180628 leukapheresis specimens from participating centers and disseminate autologous vaccine products to subjects enrolled at sites outside of the UF health network. https://www.ctsi.ufl.edu/ http://biorepository.pathology.ufl.edu/ http://gastroliver.medicine.ufl.edu/hepatology/faculty -staff/david -r-nelson -m-d/ Scott Rivkees, M.D. (Other Significant Contributor) is Professor and Chairma n of Pediatrics and Chair of the Child Health Research Institute at the University of Florida . Dr.